Saturday 17 October 2026
Export RNLXY’s income statement to Excel — free account
Renalytix plc - Sponsored ADR
RNLXY Healthcare Health Information Services
Renalytix plc - Sponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $3.0 million, up 30.4% from fiscal 2024. Operating cash flow growth for three consecutive years.
3.50
0.11
+3.24%
Follow RNLXY
| Older periods | Jun '24 | Sep '24 | Dec '24 | Jun '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
147.79 | 116.86 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(45.23) | (71.99) | — | — | |
P/B ratio |
0.00 | 0.00 | — | — | |
Price to Tangible BV |
0.00 | 0.00 | — | — | |
EV/Sales |
147.31 | 118.22 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(11.37) | (11.58) | — | — | |
EV/FCF |
(11.23) | (11.40) | — | — | |
Quick Ratio |
0.52 | 0.15 | 2.22 | — | |
Current Ratio |
0.58 | 0.24 | 2.43 | — | |
Net Debt/EBITDA |
0.22 | (0.79) | 0.00 | — | |
Debt/Assets |
60.56% | 85.52% | 71.72% | 0.00% | |
Debt/Equity |
(0.48) | (0.36) | (5.99) | — | |
Asset Turnover |
0.12 | 0.19 | 0.00 | 0.00 | |
Operating CF/Net income |
0.39 | 0.81 | 0.00 | — | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Research and Development Expense of Revenue |
177.89% | 176.44% | — | — | |
Selling, General and Administrative Expense of Revenue |
2,587.60% | 626.63% | — | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
(31.99%) | 48.66% | 0.00% | — | |
Graham Net Nets |
(0.03) | (0.05) | — | — | |
Graham Number |
44.30 | 46.41 | — | — | |
Earnings Yield |
(13.39%) | (13.69%) | — | — | |
Free Cash Flow Yield |
(8.88%) | (8.87%) | — | — | |
Revenue per Share |
0.28 | 0.25 | — | — | |
Operating CF per Share |
(3.47) | (1.81) | 0.00 | — | |
Capex per Share |
0.00 | 0.00 | — | — | |
Free Cash Flow per Share |
(3.47) | (1.81) | 0.00 | — | |
Cash per Share |
2.49 | 0.43 | 0.00 | — | |
Shareholders Equity per Share |
(4.15) | (5.35) | 0.00 | — | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
(4.15) | (5.35) | 0.00 | — | |
Free Cash Flow |
(7.52) | (3.84) | (6.50) | — | |
Working Capital |
(5.00) | (9.13) | 6.59 | — | |
Capital Expenditures |
0.00 | — | — | — | |
Net Current Asset Value |
(9.30) | (13.23) | (1.62) | — | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
0.74 | 0.96 | 0.94 | — | |
Average Payables |
5.27 | 4.48 | 3.71 | — | |
Average Inventory |
0.20 | — | 0.42 | — | |
Average Assets |
18.86 | 12.17 | 11.36 | 4.38 | |
Average Common Equity |
(1.02) | (6.40) | (4.66) | — |
Columns are period end dates